(Q36707077)

English

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

scientific article published on 21 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial (English)

1 reference

Europe PubMed Central

15 August 2017

zoledronic acid

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

David Matheson

16

0 references

object named as

John D Graham

29

0 references

Gerhardt Attard

object named as

Gerhardt Attard

10

0 references

object named as

John Wagstaff

46

0 references

Matthew R Sydes

object named as

Matthew R Sydes

2

0 references

object named as

Duncan B McLaren

34

0 references

11

object named as

Johann de Bono

1 reference

Europe PubMed Central

15 August 2017

George N Thalmann

14

object named as

George Thalmann

1 reference

Europe PubMed Central

15 August 2017

3

object named as

Noel W Clarke

1 reference

Europe PubMed Central

15 August 2017

David P Dearnaley

5

object named as

David P Dearnaley

1 reference

Europe PubMed Central

15 August 2017

Melissa L Spear

6

object named as

Melissa R Spears

1 reference

Europe PubMed Central

15 August 2017

17

object named as

Robin Millman

1 reference

Europe PubMed Central

15 August 2017

20

object named as

Alison J Birtle

1 reference

Europe PubMed Central

15 August 2017

Prabir Chakraborti

23

object named as

Prabir Chakraborti

1 reference

Europe PubMed Central

15 August 2017

Simon Chowdhury

24

object named as

Simon Chowdhury

1 reference

Europe PubMed Central

15 August 2017

26

object named as

Tony Elliott

1 reference

Europe PubMed Central

15 August 2017

John Hetherington

30

object named as

John Hetherington

1 reference

Europe PubMed Central

15 August 2017

33

object named as

Fiona McKinna

1 reference

Europe PubMed Central

15 August 2017

Joseph Albert Sullivan

35

object named as

Joe M O'Sullivan

1 reference

Europe PubMed Central

15 August 2017

36

object named as

Omi Parikh

1 reference

Europe PubMed Central

15 August 2017

Andrew Protheroe

38

object named as

Andrew Protheroe

1 reference

Europe PubMed Central

15 August 2017

Narayanan N Srihari

40

object named as

Narayanan Srihari

1 reference

Europe PubMed Central

15 August 2017

Mahesh K B Parmar

47

object named as

Mahesh K B Parmar

1 reference

Europe PubMed Central

15 August 2017

author name string

Nicholas D James

1

1 reference

Europe PubMed Central

15 August 2017

Malcolm D Mason

4

1 reference

Europe PubMed Central

15 August 2017

Alastair W S Ritchie

7

1 reference

Europe PubMed Central

15 August 2017

Christopher C Parker

8

1 reference

Europe PubMed Central

15 August 2017

J Martin Russell

9

1 reference

Europe PubMed Central

15 August 2017

William Cross

12

1 reference

Europe PubMed Central

15 August 2017

Rob J Jones

13

1 reference

Europe PubMed Central

15 August 2017

Claire Amos

15

1 reference

Europe PubMed Central

15 August 2017

Mymoona Alzouebi

18

1 reference

Europe PubMed Central

15 August 2017

Sharon Beesley

19

1 reference

Europe PubMed Central

15 August 2017

Susannah Brock

21

1 reference

Europe PubMed Central

15 August 2017

Richard Cathomas

22

1 reference

Europe PubMed Central

15 August 2017

Audrey Cook

25

1 reference

Europe PubMed Central

15 August 2017

Joanna Gale

27

1 reference

Europe PubMed Central

15 August 2017

Stephanie Gibbs

28

1 reference

Europe PubMed Central

15 August 2017

Robert Hughes

31

1 reference

Europe PubMed Central

15 August 2017

Robert Laing

32

1 reference

Europe PubMed Central

15 August 2017

Clive Peedell

37

1 reference

Europe PubMed Central

15 August 2017

Angus J Robinson

39

1 reference

Europe PubMed Central

15 August 2017

Rajaguru Srinivasan

41

1 reference

Europe PubMed Central

15 August 2017

John Staffurth

42

1 reference

Europe PubMed Central

15 August 2017

Santhanam Sundar

43

1 reference

Europe PubMed Central

15 August 2017

Shaun Tolan

44

1 reference

Europe PubMed Central

15 August 2017

David Tsang

45

1 reference

Europe PubMed Central

15 August 2017

STAMPEDE investigators

48

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

21 December 2015

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

387

1 reference

Europe PubMed Central

15 August 2017

1163-1177

1 reference

Europe PubMed Central

15 August 2017

10024

1 reference

Europe PubMed Central

15 August 2017

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Enzalutamide in metastatic prostate cancer before chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Speeding up the evaluation of new agents in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

30 September 2017

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 fac

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

5 September 2018

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

5 September 2018

STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

5 September 2018

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

5 September 2018

Monitoring pairwise comparisons in multi-armed clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4800035

5 September 2018

Identifiers

10.1016/S0140-6736(15)01037-5

1 reference

Europe PubMed Central

15 August 2017

release_6ju735niavhzxmdndu6hj5yjya

1 reference

https://api.fatcat.wiki/v0/release/6ju735niavhzxmdndu6hj5yjya

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36707077&oldid=1858244336"